Evidence map›Paper›PMID 40537982›Full record

ReviewJournal of gynecologic oncology2025

The application of liquid biopsy techniques in cervical cancer diagnosis, prediction and therapeutic surveillance.

Jia Jiang, Libo Li, Cui Zhang, Can Yang, Yunmeng Dai, Yanping Chen, Yisidan Huang, Lu Xie, Yang Xiang, Jia Yuan and 5 more

Abstract readReview
In one paragraph

Review in Journal of gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jia Jiang *Guizhou University of Traditional Chinese Medicine, Guiyang, China.ORCID 0009-0001-0572-4871
Libo Li *Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.ORCID 0000-0002-4979-9402
Cui Zhang *Zunyi Medical University, Zunyi, China.ORCID 0009-0003-9357-7086
Can Yang *Guizhou University of Traditional Chinese Medicine, Guiyang, China.ORCID 0000-0002-4900-5270
Yunmeng DaiDepartment of Medical Imaging, Guizhou Provincial People's Hospital, Guiyang, China.ORCID 0000-0002-5543-686X
Yanping ChenDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.ORCID 0000-0001-6941-3119
Yisidan HuangZunyi Medical University, Zunyi, China.ORCID 0009-0001-5663-5123
Lu XieGuizhou University of Traditional Chinese Medicine, Guiyang, China.ORCID 0009-0002-8088-2877
Yang XiangDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.ORCID 0000-0002-2639-4541
Jia YuanDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.ORCID 0000-0002-1811-0852
Yuting ZengDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.ORCID 0000-0002-9511-1808
Qiao WangDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.ORCID 0000-0002-3444-0237
Yuncong LiuDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China. 20108557@qq.com.ORCID 0009-0004-0522-4721
Hanqun ZhangDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China. hanqun03111115@163.com.ORCID 0000-0002-8146-0337
Yong LiDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China. liyong7229771@163.com.ORCID 0000-0002-6018-6965

Funding

Application and Industrialization of Scientific and Technological Achievements of Guizhou Provincial Department of Science and Technology LC [2024]063
6 · The paper itself

Abstract

Cervical cancer (CC) is a significant cause of cancer-related deaths in women and ranks as the fourth most common malignant tumor worldwide. Cervical histopathology is currently the primary diagnostic method for confirming the presence of CC. Tumor markers and imaging techniques play crucial roles in monitoring treatment effectiveness and prognostic follow-up. Unfortunately, these traditional examination methods are invasive and often lack sensitivity and accuracy. Therefore, there is a need for a less invasive and more sensitive test to facilitate early diagnosis, efficacy evaluation, and prognostic monitoring of CC. In recent years, liquid biopsy has been developed as a new detection method. It involves analyzing tumor components released into the peripheral circulation, such as cell-free RNA, circulating tumor DNA, circulating tumor cells, tumor-educated platelets, and exosomes. Liquid biopsy offers advantages such as being less invasive, highly reproducible, and capable of real-time monitoring. Moreover, liquid biopsy can play a crucial role in the early diagnosis of CC, guiding targeted therapy, assessing prognosis, and evaluating treatment effectiveness. This review focuses on the value of liquid biopsy application in CC, detection markers, and detection methods. It also explores how liquid biopsy can be used in the detection, prognosis, and monitoring the progression of CC. The advantages and limitations of liquid biopsy in CC are analyzed to promote its application and improve the diagnosis and treatment of the disease.

Indexed as

Uterine Cervical NeoplasmsBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNAEarly Detection of CancerFemaleHumansLiquid BiopsyNeoplastic Cells, CirculatingPrognosisBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNACervical CancerCirculating Tumor CellsCirculating Tumor DNAExosomesLiquid Biopsy

Identifiers

PMID40537982
PMCPMC12636128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.